Phenotypes Associated with This Genotype

Genotype
MGI:5309137

• Allelic Composition: Rhbdf2^tm1Mak/Rhbdf2^tm1Mak
• Genetic Background: B6.129P2-Rhbdf2^tm1Mak

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

increased susceptibility to bacterial infection induced morbidity/mortality ( J:179653 )

• succumb more rapidly following infection with Listeria monocytogenes compared to wild-type controls

• die following infection with Listeria monocytogenes doses that are non-lethal in wild-type controls

decreased susceptibility to infection induced morbidity/mortality ( J:179653 )

• prolonged survival following LPS and D-galactosamine treatment

immune system

abnormal B cell physiology ( J:179653 )

• B cells stimulated with the nucleotide analog 2' (3')-O-(4-benzoyl)benzoyl adenosine 5'-triphosphate (BzATP) show inhibited CD62L shedding

abnormal immune serum protein physiology ( J:179653 )

decreased circulating tumor necrosis factor level ( J:179653 )

• following stimulation with LPS or LPS and D-galactosamine

decreased tumor necrosis factor secretion ( J:179653 )

• in culture LPS stimulated thioglycollate-elicited peritoneal macrophages shed less TNF into the media despite showing similar levels of mRNA upregulation and have increased levels of membrane bound protein

increased susceptibility to bacterial infection ( J:179653 )

• higher bacterial loads in the spleen, liver, kidney, and brain following infection with Listeria monocytogenes compared to wild-type controls

increased susceptibility to bacterial infection induced morbidity/mortality ( J:179653 )

• succumb more rapidly following infection with Listeria monocytogenes compared to wild-type controls

• die following infection with Listeria monocytogenes doses that are non-lethal in wild-type controls

decreased susceptibility to infection induced morbidity/mortality ( J:179653 )

• prolonged survival following LPS and D-galactosamine treatment

liver/biliary system

abnormal liver physiology ( J:179653 )

• decrease in amount of liver damage induced by LPS and D-galactosamine treatment

homeostasis/metabolism

decreased circulating tumor necrosis factor level ( J:179653 )

• following stimulation with LPS or LPS and D-galactosamine

hematopoietic system

abnormal B cell physiology ( J:179653 )

• B cells stimulated with the nucleotide analog 2' (3')-O-(4-benzoyl)benzoyl adenosine 5'-triphosphate (BzATP) show inhibited CD62L shedding